Design of a mobile application and evaluation of its effects on clinical outcomes in patients with dry eye disease: a study protocol for a randomized controlled trial Authors: Maryam Edalati Khodabandeh, Razieh Farrahi, Mahdi Sargolzaei, Morteza Mohammadi, Amir Hossein Edalati Khodabandeh, Siamak Zarei-Ghanavati, Saeid Eslami Published: 2026 ABSTRACT BackgroundDry eye is a common ocular surface disorder resulting from tear deficiency or excess tear evaporation. This protocol will be implemented for a study designed to determine the effectiveness of a mobile self-care application on objective clinical test results and subjective symptoms in patients with dry eye disease.MethodsThe first stage will include the development of a mobile self-care application using the Python framework of Flask technology and SQLite database in the backend, and the Flutter framework of Dart for the bot technology in the front end. The second stage will be conducted using a two-arm blinded randomized clinical trial. The sample size calculation initially targeted 104 patients with dry eye disease, intended for division into intervention and control groups via an online random number generator. However, unforeseen challenges, including COVID-19 disruptions, led to randomization of 181 patients (91 intervention, 90 control).This resulted in 104 completers after a 42.5% dropout rate. Patients in both groups will receive usual medical care, but those in the intervention group will also use a mobile-based application for a period of 12 weeks. Study outcomes including the Tear Break-Up Time clinical test as the primary outcome, and the validated Persian version of the Ocular Surface Disease Index questionnaire as a secondary outcome measure in patients with dry eye disease, will be assessed at 6- and 12-weeks post-baseline.DiscussionIt is expected that delivering customized training via a mobile application during clinical visits would promote improvement and reduction of disease severity, as well as strengthen the physician-patient relationship. This study was developed by an interdisciplinary research team in accordance with current dry eye disease guidelines and taking into account the medical history and classification of dry eye disease. Considering the lack of financial resources for traditional self-care methods and the development of technologies based on mobile health, it seems that one can hope for the acceptance of such systems in the patients with dry eyes.Trial registrationThis protocol is registered in the Iranian registration of clinical trial (IRCT) with the code IRCT20200721048162N1. Registered 31 August 2020, URL: https://irct.behdasht.gov.ir/trial/49779.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-025-09189-8. Introduction Dry eye disease (DED) is a multifactorial condition that disrupts the tear film and eye surface, leading to symptoms like dryness and ocular irritation [1]. DED usually worsens during the day, disrupting patients’ daily activities and reducing their quality of life. In severe cases, it can lead to complications such as corneal scarring, bacterial keratitis, and severe vision loss [2]. According to clinical guidelines, there are various and often expensive treatments [3] available for this disease. However, sometimes the disease persists in an uncertain condition despite these treatment methods. Therefore, educating patients about the internal and external factors that play a role in the development and exacerbation of this disease, especially during the exacerbation of symptoms, is very important. In fact, the most important step in preventing and controlling eye dryness is providing proper education to the patients [4]. One cost-effective intervention [5–9] for motivating patients for self-care can be the use of mobile health applications [10, 11]. These interventions create a new opportunity for patients to actively participate in monitoring personal health indicators [12]. Therefore, in this study, the Dry Eye Digital as mobile self-care application trial protocol is described to determine the effectiveness of self-care education provided via mobile phone on improving clinical test outcomes (objective tests) and subjective patient-reported tests in patients with DED. It is expected that the customized education delivered through the mobile application will aid in the improvement and treatment of patients. Materials and methods Study design This randomized, single-center, two-arm, controlled parallel trial (RCT) protocol aims to assess the effect of a mobile self-care application intervention on primary and secondary outcome measures in patients with dry eye disease at 6- and 12-weeks post-baseline. This RCT employs a superiority framework to evaluate whether the mobile self-care application (combined with usual care) yields statistically and clinically significant improvements in clinical outcomes (TBUT) and subjective symptoms (OSDI scores) compared to usual care alone in dry eye disease patients. This protocol will be conducted in alignment with established guidelines including " SPIRIT 2013 statement: defining standard protocol items for clinical trials " [13], and intervention reporting will adhere to the Consolidated Standards of Reporting Trials of Electronic and Mobile Health Applications and online Telehealth (CONSORT-EHEALTH) criteria [14]. The total study duration is 18 months, with an intervention period of 12 weeks per participant, encompassing sequential stages of needs assessment, content development, mobile application design and usability evaluation, participant recruitment, randomization, group allocation, intervention delivery, longitudinal follow-up assessments, and data analysis (Fig. S1). Randomization and allocation concealment Following the ophthalmologist's examination of the patients, a total of 104 individuals were systematically allocated into two distinct arms: an intervention group receiving usual care in conjunction with the mobile application, and a control group exclusively receiving usual care. The allocation process employed an online random number generator available at www.randomization.com, ensuring an equitable distribution of participants between the intervention and control groups at a 1:1 ratio. This randomized assignment aims to enhance the scientific rigor of the study, minimizing potential biases and enabling a more robust evaluation of the intervention's impact on patient outcomes. The sequence of randomly generated numbers is concealed within sealed envelopes by a member of the research team. For patients meeting the inclusion criteria, the randomization envelope is opened, and each patient is subsequently assigned to one of the groups. Follow-up sessions are free for the patients participating in this study. Blinding and consenting The nature of the intervention precludes participant blinding; however, patients will be informed about the study design, including the existence of two research groups, but will remain unaware of their specific group allocation. The data manager, who generates the randomization sequence and prepares the allocation envelopes, along with the statistician responsible for data analysis, will remain blinded to group assignments. After confirming the dry eye diagnosis through clinical examination, the study objectives are thoroughly explained to patients. Written informed consent is then obtained by the researcher prior to enrollment in the study. Baseline measurement Upon completion of the consent form, demographic data, encompassing gender, age, education level, occupation, contact number, email, and residential address, will be systematically gathered from the participating patient. Participants and setting Our target population is patients with dry eyes. The inclusion consists of:at least 18 years of age,not having mental or psychological disorders,Being literate in reading and writing, access to a smart mobile phone (the patient or their companions) and the ability to use it. at least 18 years of age, at least 18 years of age, not having mental or psychological disorders, not having mental or psychological disorders, Being literate in reading and writing, access to a smart mobile phone (the patient or their companions) and the ability to use it. Being literate in reading and writing, access to a smart mobile phone (the patient or their companions) and the ability to use it. Exclusion criteria consist of:Non-participation in a similar projectLack of consent to participate and receive trainingInability to use the Internet and electronic devices due to severity of dry eye disease Non-participation in a similar project Non-participation in a similar project Lack of consent to participate and receive training Lack of consent to participate and receive training Inability to use the Internet and electronic devices due to severity of dry eye disease Inability to use the Internet and electronic devices due to severity of dry eye disease This prospective study will be carried out at the NoorAfrin Ophthalmology Clinic located in Mashhad, Razavi Khorasan Province, Iran. Patients diagnosed with dry eye disease by the attending physician based on clinical examination findings will be referred to the study team. Eligible patients will be enrolled after providing informed consent and receiving details regarding study participation. Patients will be visited and evaluated at 6 and 12 weeks after baseline. A flowchart of trial progress (e.g., recruitment, randomization, intervention allocation, follow-up, and data analysis are shown in Fig. 1.Fig. 1A flowchart of trial progress A flowchart of trial progress System development Step1: needs assessment The software requirements were determined by the programming team during numerous meetings with medical informatics and ophthalmologists. Additionally, in the present study, patient education materials will be developed to disseminate medical information pertaining to dry eye disease, with the aim of encouraging patient self-care activities. Based on a review of relevant literature [15–21] and the opinion of the research team (comprising 8 ophthalmologists and 2 medical informaticians), a questionnaire was designed to identify which educational topics were highest priority from the patients' perspective. Following analysis of the questionnaire data, the priority ranking of educational topics relating to therapeutic and lifestyle modifications was determined. Step 2: content development In September of 2021, we systematically developed the educational content through a three-step process. First, we conducted a comprehensive search of English and Persian sources, including peer-reviewed literature, clinical guidelines (TFOS DEWS II [22]), and authoritative websites such as UpToDate. We then extracted, translated, and thematically categorized the materials. To validate these materials, three independent ophthalmologists (with an average of 14 years of experience) conducted a structured review that included: (1) verification of scientific accuracy against current evidence, (2) assessment of clinical relevance (aligned with severity Grades 1-4 from OSDI/TBUT), and (3) linguistic and thematic refinement. The expert system subsequently matched educational content to individual patients using a rule-based algorithm that considered both severity grade (from diagnostic tests) and medical history data. This dual validation approach - combining clinical expert review with algorithmic personalization - ensured delivery of evidence-based, patient-specific content. Step3: application design process The backend of the system has been written using the Python Flask framework and SQLite database technology. The frontend has been developed with the Flutter framework using Dart technology. After designing and testing the application, it is installed for patients randomly selected in the intervention group. Following their initial registration and completion of the medical history, customized educational materials are sent to the patients on a weekly basis. Study arms Usual care This group of patients receives usual care, which includes taking a medical history, eye examinations, prescription of medications, and receiving recommendations and treatment-related instructions from their attending physician during the visit. Intervention Addition to usual care, patients in the intervention group will utilize the mobile self-care application called Dry Eye Digital for a duration of 12 weeks. After patients are diagnosed with dry eye and enrolled in the study, the software will be installed on their mobile phones and the patient is asked to complete their clinical history and questionnaire. Given the potential risk factors linked to mobile phone usage in patients with this disease, the protocol specified sending one educational material and one therapeutic exercise to each participant weekly. The application will record the designated dates for patient visits at the 6-week and 12-week intervals. Participants will receive automated reminders regarding their upcoming visits, both two days before and on the morning of the scheduled appointment. The educational materials will be customized to each participant based on their medical history and diagnostic test findings (The messages are customized for each individual). To promote participant adherence and retention throughout the trial, the research team will implement the following strategies in addition to free follow-up visits and automated application-based alarms and notifications for questionnaire completion: in cases of non-adherence, participants will be encouraged via telephone follow-up calls to complete the required questionnaires. During these calls, the team will emphasize the importance of compliance and explain that updated educational content, tailored to the participant’s current disease status, will be activated and accessible only upon questionnaire completion. These measures are designed to enhance engagement, minimize attrition, and ensure complete follow-up data collection. Data collection and management For the control group, all data—including questionnaires and clinical test results—will be collected using paper-based forms during clinic visits. Data from both groups will subsequently be transferred securely and entered into a Microsoft Excel database for analysis. To minimize entry errors, data entry into the electronic database will be conducted by trained investigators following standardized protocols. Although paper-based Case Report Forms (CRFs) will be employed for the control group, rigorous procedures will be implemented to ensure secure handling, storage, and transfer of these documents to the trial office, in compliance with data protection guidelines and ethical committee standards. Data quality processes To ensure data quality, patients’ clinical data and OSDI questionnaires will be reviewed by a second trained investigator at the end of each clinic visit day for accuracy, precision, and completeness. Furthermore, the final dataset will undergo random range checks by the research team prior to analysis. Data storage Data from the intervention group will be stored electronically on a secure, dedicated server. Outcome measure Primary outcome The primary outcome will be the Tear Break-Up Time (TBUT) clinical test, assessed at baseline, 6 weeks, and 12 weeks. TBUT values below 10 seconds are associated with an unstable tear film and increased susceptibility to dry eye disease [22]. Secondary outcomes To evaluate this outcome, the validated Persian version of the Ocular Surface Disease Index (OSDI) questionnaire will be utilized. This outcome will also be assessed at baseline, 6 weeks, and 12 weeks. The 12-item OSDI tool stratifies results into four severity categories: normal (0-12), mild (13-22), moderate (23-33), and severe (34-100). Each OSDI item is graded on a 5-point Likert scale (0 = never to 4 = always). Participants with a total OSDI score ≥13 are classified as having dry eye disease [6, 22]. Sample size The sample size was calculated using the established formula for pilot clinical trials [23] to detect a clinically meaningful effect with 80% power at a 5% significance level. Assuming equal allocation (r=1), estimated variance (σ2), and anticipated effect size (d), 52 participants per group (total 104) were required. This calculation was confirmed using G*Power (v3.1.9.7) [24] and reviewed by expert ophthalmologists, considering clinic-specific recruitment feasibility (approximately two dry eye patients per day) over an 18-month period. Although attrition was initially expected to be low due to automated reminders and free follow-ups, an observed dropout rate of 42.5%—mainly due to COVID-19 disruptions—necessitated intention-to-treat analysis with multiple imputation to reduce bias [25]. Future studies will adjust sample sizes accordingly (n_adjusted = n_original / (1 - dropout_rate)) following SPIRIT 2013 guidelines. This rigorous approach supports the trial’s novelty as Iran’s first randomized controlled mHealth intervention for dry eye disease.\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$n=\frac{\left(r+1\right){\left({z}_{1-\beta }+{z}_{1-\frac{\alpha }{2}}\right)}^{2}{\sigma }^{2}}{r{d}^{2}}$$\end{document}n=r+1z1-β+z1-α22σ2rd2 Statistical analysis The normality of the quantitative data will first be assessed using the Kolmogorov-Smirnov test. If the data passes the normality test, confirming an approximate normal distribution, the quantitative variables will then be summarized using the mean and standard deviation. To assess homogeneity of qualitative variable distributions across control and intervention arms, Pearson's chi-squared test will be utilized at a significance level of 0.05. If normal data distribution is found, paired sample t-tests will be utilized for within-group mean comparisons of the control and intervention arms separately at each specified time point. Additionally, to evaluate mean differences for normally distributed quantitative variables between the two study arms, independent sample t-tests will be conducted separately. Statistical analyses will adhere to the intention-to-treat principle and be conducted using SPSS version 25 software. No additional, subgroup, or adjusted analyses beyond those prespecified in this protocol are planned. Post hoc analyses not defined a priori will not be performed, to minimize risks of data dredging and p-hacking. Missing data due to participant dropouts or incomplete assessments will be addressed using multiple imputation under the missing at random (MAR) assumption to reduce bias. Primary analyses will follow the intention-to-treat (ITT) principle, including all randomized participants regardless of adherence. Sensitivity analyses comparing ITT and per-protocol results will be conducted to evaluate the impact of non-adherence. Although mixed-effects models are effective for handling missing longitudinal data, multiple imputation combined with ITT analysis is preferred given the study’s sample size and design, with the option to use mixed models if indicated by further analyses. No interim analyses or formal stopping rules, including O’Brien-Fleming boundaries, are planned for this trial due to the short duration and low anticipated risk to participants. The study team will continuously monitor for adverse events, and any serious safety concerns will be reviewed by the ethics committee to determine if early termination is warranted. Discussion This study is the protocol for a randomized clinical trial that is designed to determine the effectiveness of a mobile self-care application on objective clinical test results and subjective symptom in patients with dry eye disease. It is expected that delivering customized training via a mobile application during clinical visits would promote improvement and reduction of disease severity, as well as strengthen the physician-patient relationship. This study was developed by an interdisciplinary research team in accordance with current dry eye disease guidelines and taking into account the medical history and classification of dry eye disease. Considering the lack of financial resources for traditional self-care methods and the development of technologies based on mobile health, it seems that can hope for the acceptance of such systems in the patients with dry eyes. Numerous studies have demonstrated that mobile-based interventions can be effective across all stages, including diagnosis, prevention, treatment, and follow-up, by assessing symptoms, risk factors, treatment compliance, physician-patient relationship, patient education, and health literacy promotion [6, 7, 26]. Based on the results, most of the studies using technology in ophthalmology have been conducted for the diagnosis of eye diseases such as glaucoma, cataracts, and red eyes [27–33]. According to the researchers in this study, an intervention based on information technology has not been used to improve the clinical outcomes of dry eye patients in Iran to date. If effective, this trial will be the first interventional study that shows the effect of mHealth in improving treatment outcomes in dry eye patients in a randomized controlled trial, although the effectiveness of the intervention will be dependent on the active participation of patients. Furthermore, given the increasing prevalence of dry eye disease as a result of climate change and the substantial costs associated with its treatment, a practical and cost-effective approach, such as technology-based interventions for self-care education, has become a fundamental necessity in this field [3, 34]. Trial status This is protocol version: 1. 2(dated 5May 2021) and Patient registration started on 2021/04/04. Due to the fact that the registration of patients coincided with the outbreak of Corona in Iran and the patients did not come for their follow-up and follow up on the continuation of their treatment, the duration of patient admission was postponed, and patient admission continued until 2024. Recruitment is expected to end on 2024 August 31. Supplementary Information Additional file 1. Figure 1. Schematic presentation of study’s timelineAdditional file 2. SPIRIT Checklist for Trials. Additional file 1. Figure 1. Schematic presentation of study’s timeline Additional file 2. SPIRIT Checklist for Trials.